Liquidia Corp LQDA
Institutional shares held
45.1 Million
473K
calls
464K
puts
Total value of holdings
$749M
$7.85M
calls
$7.7M
puts
Market Cap
$1.07B
64,362,300
Shares Out.
Institutional ownership
70.07%
# of Institutions
189
We take great care to ensure that the data presented and summarized in this overview for Liquidia Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LQDA
View all-
Black Rock Inc. New York, NY4.24MShares$70.4 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.99MShares$66.2 Million0.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$57.5 Million0.0% of portfolio
-
Findell Capital Management LLC New York, NY2.89MShares$48 Million20.5% of portfolio
-
Opaleye Management Inc. Boston, MA2.26MShares$37.5 Million9.17% of portfolio
-
State Street Corp Boston, MA1.79MShares$29.7 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.64MShares$27.2 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.62MShares$26.8 Million0.6% of portfolio
-
Patient Square Capital LP Menlo Park, CA1.52MShares$25.3 Million9.29% of portfolio
-
Geode Capital Management, LLC Boston, MA1.37MShares$22.8 Million0.0% of portfolio
Latest Institutional Activity in LQDA
Top Purchases
Top Sells
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Insider Transactions at LQDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,526
-0.93%
|
$35,364
$14.54 P/Share
|
|
Jul 14
2025
|
Sarah Krepp Chief Human Resource Officer |
SELL
Open market or private sale
|
Direct |
2,673
-1.84%
|
$37,422
$14.28 P/Share
|
|
Jul 14
2025
|
Scott Moomaw Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,797
-2.1%
|
$67,158
$14.28 P/Share
|
|
Jul 14
2025
|
Rajeev Saggar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,327
-1.92%
|
$74,578
$14.28 P/Share
|
|
Jul 14
2025
|
Russell Schundler General Counsel |
SELL
Open market or private sale
|
Direct |
7,836
-1.34%
|
$109,704
$14.28 P/Share
|
|
Jul 14
2025
|
Jason Adair Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,576
-1.31%
|
$36,064
$14.28 P/Share
|
|
Jul 14
2025
|
Dana Boyle Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,193
-0.63%
|
$16,702
$14.28 P/Share
|
|
Jul 14
2025
|
Roger Jeffs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,504
-1.91%
|
$567,056
$14.28 P/Share
|
|
Jul 14
2025
|
Michael Kaseta CFO and COO |
SELL
Open market or private sale
|
Direct |
11,580
-2.77%
|
$162,120
$14.28 P/Share
|
|
Jul 11
2025
|
Scott Moomaw Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,107
+1.34%
|
-
|
|
Jul 11
2025
|
Rajeev Saggar Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,531
+1.26%
|
-
|
|
Jul 11
2025
|
Russell Schundler General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,759
+0.64%
|
-
|
|
Jul 11
2025
|
Jason Adair Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,475
+1.25%
|
-
|
|
Jul 11
2025
|
Roger Jeffs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,666
+1.29%
|
-
|
|
Jul 11
2025
|
Michael Kaseta CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,828
+1.38%
|
-
|
|
Jul 01
2025
|
Dana Boyle Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+11.72%
|
-
|
|
Jul 01
2025
|
Sarah Krepp Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+14.69%
|
-
|
|
Jun 17
2025
|
Stephen M Bloch Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
|
Jun 17
2025
|
Damian De Goa Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+17.54%
|
-
|
|
Jun 17
2025
|
Joanna Horobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,396
+32.19%
|
-
|
Last 12 Months Summary
Buy / Acquisition
2.71M
Shares
From
26
Insiders
| Grant, award, or other acquisition | 1.97M shares |
|---|---|
| Open market or private purchase | 487K shares |
| Exercise of conversion of derivative security | 253K shares |
| Open market or private sale | 459 shares |
Sell / Disposition
3.9M
Shares
From
10
Insiders
| Open market or private sale | 461K shares |
|---|---|
| Other acquisition or disposition | 3.44M shares |